LMMY OTC
Exousia Bio, Inc.
1W: +5.6%
1M: -48.8%
3M: -96.1%
YTD: -95.5%
1Y: -90.6%
$0.02
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.1M
52W Range0.012-0.94
Volume20,022
Avg Volume27,828
Beta0.00
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOMatthew Dwyer
Employees2
SectorConsumer Defensive
IndustryEducation & Training Services
IPO Date2024-10-01
Websiteexousiabio.com
7901 4th Street N #23494
Saint Petersburg, FL 33702
US
Saint Petersburg, FL 33702
US
657-315-8312
About Exousia Bio, Inc.
Exousia Bio, Inc. is a biotechnology company that designs, develops, and manufactures mammalian- and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company's platform enables the custom production of exosomes with enhanced genetic functionality that can selectively target specific cells to address diseases. The company was formerly known as LAMY and changed its name to Exousia Bio, Inc. in January 2026.
Latest News
Exousia Pro, Inc. Completes Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms
LAMY Completes Strategic Acquisition of Cancer Therapy Innovator Exousia AI, Inc.
LAMY Completes Strategic Acquisition of Cancer Therapy Innovator Exousia AI, Inc.
Recent Insider Trades
No insider trades found